Modulation of endogenous β-tubulin isotype expression as a result of human βIII cDNA transfection into prostate carcinoma cells
2001
Effects of β-tubulin Isotype Changes in Prostate Cancer Cells
publication
Evidence: moderate
Author Information
Author(s): Ranganathan S, McCauley R A, Dexter D W, Hudes G R
Primary Institution: Penn State College of Medicine, Dept of Pharmacology
Hypothesis
Does the transfection of βIII cDNA into prostate carcinoma cells affect their drug resistance to antimicrotubule agents?
Conclusion
Transfecting βIII isotype into prostate carcinoma cells did not make them resistant to antimicrotubule drugs.
Supporting Evidence
- The study showed a 7-fold increase in βIII tubulin levels in transfected cells compared to controls.
- Cell viability assays indicated similar drug sensitivity between βIII transfected and vector control cells.
Takeaway
The study tried to see if adding a specific protein to cancer cells would help them resist certain drugs, but it didn't work.
Methodology
Prostate carcinoma cells were transfected with βIII cDNA and analyzed for protein expression and drug sensitivity.
Limitations
The study did not explore other potential factors influencing drug resistance.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website